(C) Wolf G Kroner 2014 - Prof. Christof von KalleTransition: Cancer Research Translation

September 2014. Companies offering cancer diagnostics or drugs abound. A few successful products are efficient and evidence attractive opportunities for profit-making, which fuel investors’ fantasies in turn. However translation of cancer research into a broader spectrum of tangible clinical results – paediatric or geriatric ones – continues to fall short of high hopes.

In the exclusive conversation with B2Bioworld Christof von Kalle, Head of the National Center for Tumor Diseases (NCT) at Heidelberg provides a sense of how wishful wangling or group think lead up to deadends in personalised medicine. NCT is a dozens of million Euros translational venture by the German Cancer Research Center (DKFZ), German Cancer Aid, biobanks and university hospitals in the Rhine-Neckar region. It services drug companies like AbbVie/Abbott, Boehringer Ingelheim, Merck Serono, Roche, or recently Sanofi. It has stakes in molecular diagnostics and radiological imaging accompanied by SAP-investors and others.

What is at issue in research on checkpoint inhibitors, cancer stem cells, myelodysplastic syndromes, lung cancers or other tumours? How beneficial are the European Medicines Agency’s or the UK pharma’s initiatives to open up access to clinical trials data for R&D centres like NCT? What about French regulatory requirements? When does a hype of research about molecular cancer biomarkers achieve the opposite? An enriching perspective on delicate issues.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Article free of advertisement - 12 pages
- Includes additional information, for example on collaborations with INSERM and Sanofi,
as well as on HolsboerMaschmeyer

Full Company License enquire here

Back to section

Related Editorial Articles

Merck: Getting closer to biosimilars markets in Asia and Latin America

Is that worth a dollar, or a million dollars?
Ed Torres, Managing Director of Lilly Ventures on the Fund’s input to Eli Lilly’s business development

Close-up: National Center for Tumor Diseases Heidelberg
An independent and non-sponsored look by B2Bioworld Editors

Patenting Stem Cells – Behind the Front Stages
The patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Bayer AG: New Stakes in Stem Cells
Andreas Busch, responsible for Global Drug Discovery of Bayer AG offers insights for technology as well as business developers and venture capital

Thermo Fisher’s BRIMS-Strategy Under Testing
An independent and non-sponsored look into an industry translation venture to move its mass spectrometry into academic biomarker research

Improving the IP System on a global scale: A view from Japan
Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Easier Access to Patent Claims Encoded in Chinese

Stem Cells – Failings and Deliveries
Hugh Ilyine, longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Leroy Hood: Thinking Further about Stem Cells

The Myriad Way
Peter D Meldrum, past CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia